For the Quarter Ending June 2022
During Q2 2022, the Clopidogrel Bisulfate prices showcased a declining trend in the U.S. market amidst the rising interest rates. As per market players, the business sentiment remained optimistic regarding demand, but firms continue to note supply chain and pricing issues as their biggest concerns remained elevated due to energy, fuel, transportation, and material prices. Additionally, due to stable buyer demand and the impact of further inflationary pressure on consumer spending. At the same time, the U.S. manufacturing sector signaled subdued improvements in operating conditions during June, with domestic and foreign client demand falling. As a result, suppliers utilized their current holdings of inputs and finished goods to supplement production, with input buying stagnating and supply chain delays easing.
In the Indian market, Clopidogrel Bisulfate prices declined in the second quarter of 2022. The General Schedule (S85) limits for Clopidogrel Bisulfate and Clopidogrel Bisulfate with aspirin changed from Authority Required (Streamlined) with multiple codes to unrestricted listings on May 1, 2022, according to market participants. Prescribers had to choose the appropriate simplified authorization codes for Clopidogrel Bisulfate or Clopidogrel Bisulfate with aspirin from a long list of regulations in the prior listings. However, the National Pharmaceutical Pricing Authority (NPPA), a regulatory body for medication pricing, set retail prices for 84 prescription formulations at the end of this quarter, including those used to treat diabetes, headaches, and high blood pressure. The pricing of formulations intended to lower high levels of triglycerides and cholesterol, among other things, has also been set by the National Pharmaceutical Pricing Authority (NPPA). The NPPA has fixed the retail prices of the pharmaceuticals by the authorization granted by the Drugs (Prices Control) Order, 2013. A Rosuvastatin, Aspirin, and Clopidogrel Bisulfate capsule costs Rs. 13.91.
In the second quarter of 2022, the European Clopidogrel Bisulfate prices witnessed a plunging trend owing to the higher inventory level in the domestic market amidst weaker euro and rising interest rates. As per market players, Germany imports Clopidogrel Bisulfate from the Asian market, while the Asian market being in a dropping situation, profited the German suppliers. German traders used their piled-up inventories and cleared them at lower prices than the Asian traders as they wanted to remove the stock before the upcoming quarters. The domestic market was sluggish in the terminal market, and the cost of receiving goods in Germany dropped simultaneously. Additionally, more significant economic headwinds amid elevated inflation, the energy crisis, and supply-chain issues weighed on the demand outlook.